

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A method for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders, ~~characterized by the steps of comprising:~~

selecting at least one dry powder medicament from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments;

preparing a metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments on a common dose bed, where the sum of the metered deposits constitutes the metered quantity of powder of a medicinal combined dose;

introducing the medicinal combined dose into an inhaler device for delivery of the medicinal combined dose during the course of a single inhalation by a user, such that wherein the delivered medicinal combined dose when delivered comprises is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments respectively, whereby an intended therapeutic or treating effect to the user is achieved.

2. (Currently Amended) The method according to claim 1, ~~characterized by the further step of wherein:~~

~~using formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as from the first group of bronchodilating medicaments as a the~~ first medicament and budesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof ~~is selected as from the second group of anti-inflammatory medicaments as a second medicament.~~

3. (Currently Amended) The method according to claim 1, characterized by the further step of

using wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the from the first group of bronchodilating medicaments as a first medicament and fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the from the second group of anti-inflammatory medicaments as a second medicament.

4. (Currently Amended) The method according to claim 1, characterized by the further step of

using wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the from the first group of bronchodilating medicaments as a first medicament and mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the from the second group of antiinflammatory medicaments as a second medicament.

5. (Currently Amended) The method according to claim 1, characterized by the further step of

using wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the from the first group of bronchodilating medicaments as a first medicament and ciclesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the from the second group of antiinflammatory medicaments as a second medicament.

6. (Currently Amended) The method according to claim 1, characterized by the  
~~further step of~~

~~using wherein one or more of the substances Albuterol (also known as Salbutamol), Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanterol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, Metaproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol, Reproterol, Salmeterol, Terbutaline, Tiotropium and Tulobuterol or pharmaceutically acceptable salts, enantiomers, racemates, hydrates, solvates, or mixtures thereof is selected as the belonging to the first group of bronchodilating medicaments as a first medicament and one or more of the substances Budesonide, Beclomethasone, Ciclesonide, Dexametasone, Flunisolide, Fluticasone, Ipratropium, Mometasone and Triamcinolone or pharmaceutically acceptable salts, enantiomers, racemates, hydrates, solvates, or mixtures thereof is selected as the belonging to the second group of anti-inflammatory medicaments as a second medicament.~~

7. (Currently Amended) The method according to claim 1, characterized by the  
~~further step of~~

~~preparing wherein the dry powder medicinal combined dose to a has total mass in a range from 10 µg to 50 mg.~~

8. (Currently Amended) The method according to claim 1, characterized by the  
~~further step of further comprising~~

~~separating the deposits of the included medicaments from each other onto a the dose bed, such that the medicaments cannot detrimentally mix with each other after forming of the combined dose.~~

9. (Currently Amended) The method according to claim 1, characterized by the further step of further comprising administering said combined dose via selecting a continuous dry powder inhaler (DPI) designed for a prolonged delivery of the medicinal combined dose to a user inhaling once through the DPI.

10. (Currently Amended) A pharmaceutical dry powder combined dose, adapted for inhalation, for the prophylaxis or treatment of a respiratory disorder in a mammalian host, characterized in that

comprising at least one medicament from a first group of bronchodilating medicaments and at least one medicament from a second group of anti-inflammatory medicaments are selected;

wherein the pharmaceutical dry powder combined dose is prepared comprising comprises separate, metered deposits of a medicinally suitable quantity of the selected medicaments from the first and second groups of medicaments respectively on a common dose bed, where the sum of the deposits constitute the metered quantity of powder in the pharmaceutical, combined dose;.

~~the pharmaceutical dry powder combined dose is introduced into an inhaler device for a user initiated delivery of the pharmaceutical dry powder combined dose, whereby the first and second medicaments of the combined dose are delivered to the host user during the course of a single inhalation;~~

~~the combined therapeutical effect of the inhaled medicinal dosage comprising two selected medicaments is medically, psychologically or socially beneficial to the host user in need of such combined treatment.~~

11. (Currently Amended) The pharmaceutical dry powder combined dose according to claim 10, ~~eharaeterized in that~~ wherein:

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected ~~from the first group of bronchodilating medicaments~~ as a the first medicament and budesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected ~~from the second group of anti-inflammatory medicaments~~ as a the second medicament.

12. (Currently Amended) The pharmaceutical dry powder combined dose according to claim 10, ~~eharaeterized in that~~ wherein:

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected ~~from the first group of bronchodilating medicaments~~ as a the first medicament and fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected ~~from the second group of anti-inflammatory medicaments~~ as a the second medicament.

13. (Currently Amended) The pharmaceutical dry powder combined dose according to claim 10, ~~eharaeterized in that~~ wherein:

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected ~~from the first group of bronchodilating medicaments~~ as a the first medicament and mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected ~~from the second group of anti-inflammatory medicaments~~ as a the second medicament.

14. (Currently Amended) The pharmaceutical dry powder combined dose according to claim 10, characterized in that wherein:

formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the first group of bronchodilating medicaments as a the first medicament and ciclesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected from the second group of anti-inflammatory medicaments as a the second medicament.

15. (Currently Amended) The pharmaceutical dry powder combined dose according to claim 10, characterized in that wherein:

one or more of the substances Albuterol (also known as Salbutamol), Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanerol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, MetAproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol, Reproterol, Salmeterol, Terbutaline, Tiotropium and Tulobuterol or pharmaceutically acceptable salts, enantiomers, racemates hydrates, solvates, or mixtures thereof belonging to the first group of bronchodilating medicaments may be used is selected as a the first medicament and one or more of the substances Budesonide, Beclomethasone, Ciclesonide, Dexametasone, Flunisolide, Fluticasone, Ipratropium, Mometasone and Triamcinolone or pharmaceutically acceptable salts, enantiomers, racemates hydrates,

solvates, or mixtures thereof belonging to the second group of antiinflammatory medicaments may be used as a is selected as the second medicament.

16. (Currently Amended) The pharmaceutical dry powder combined dose according to claim 10, characterized in that wherein

the combined dose ~~is prepared to~~ has a total mass in a range from 10  $\mu\text{g}$  to 50 mg.

17. (Currently Amended) The pharmaceutical dry powder combined dose according to claim 10, ~~characterized in that~~ wherein

~~the deposits of~~ the included medicaments are suitably separated from each other onto a the dose bed, such that the medicaments cannot detrimentally mix with each other ~~after~~ upon forming of ~~the~~ a combined dose.